Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Maze Therapeutics, Inc. ( (MAZE) ) has shared an update.
Maze Therapeutics reported fourth-quarter and full-year 2025 results on March 25, 2026, alongside positive Phase 2 HORIZON topline data for MZE829 showing clinically meaningful reductions in proteinuria in APOL1-mediated kidney disease, and confirmed plans to move the program into a pivotal stage while initiating two Phase 2 trials of MZE782 in phenylketonuria and chronic kidney disease in 2026. The company also highlighted a $20 million milestone payment from Shionogi tied to Phase 2 dosing of Pompe candidate MZE001, a strengthened cash position of $360 million expected to fund operations into 2028 despite higher R&D and G&A expenses driving a 2025 net loss, and the appointment of BridgeBio founder and CEO Neil Kumar to its board, signaling a bid to deepen leadership experience as it advances a broader late-stage pipeline.
The most recent analyst rating on (MAZE) stock is a Buy with a $58.00 price target. To see the full list of analyst forecasts on Maze Therapeutics, Inc. stock, see the MAZE Stock Forecast page.
Spark’s Take on MAZE Stock
According to Spark, TipRanks’ AI Analyst, MAZE is a Neutral.
The score is driven primarily by improved 2024 financial performance (profitability and strong cash generation) and supportive technical momentum (price above key moving averages with positive MACD). These positives are tempered by valuation limitations from a negative P/E and the still-volatile multi-year financial history, while the new loan facility modestly strengthens liquidity but adds secured debt and covenant risk.
To see Spark’s full report on MAZE stock, click here.
More about Maze Therapeutics, Inc.
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel small molecule precision medicines for patients with kidney and metabolic diseases. Guided by its Compass platform, the South San Francisco-based firm focuses on genetically validated targets, led by APOL1 inhibitor MZE829 for APOL1-mediated kidney disease and SLC6A19 inhibitor MZE782 for phenylketonuria and chronic kidney disease.
Average Trading Volume: 496,159
Technical Sentiment Signal: Strong Buy
Current Market Cap: $2.36B
Learn more about MAZE stock on TipRanks’ Stock Analysis page.